Interpace Biosciences, Inc.
IDXG
Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024. In the quarter to June 2026, revenue fell 1.09%, EPS grew 104.1% and free cash flow fell 92.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.
Follow IDXG
Interpace Biosciences, Inc. (IDXG) EV/Sales
As of 9 October 2026, Interpace Biosciences, Inc. (IDXG) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from 0.0× (January 2026) to 1.2× (August 2026); the current reading is higher than 95% of that period.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.0× | (53.94%) |
| FY2024 | 0.1× | 84.10% |
| FY2023 | 0.0× | 0.00% |
| FY2022 | 0.0× | 0.00% |
| FY2021 | 0.0× | 0.00% |
| FY2020 | 0.0× | 0.00% |
| FY2019 | 0.0× | 0.00% |
| FY2018 | 0.0× | 0.00% |
| FY2017 | 0.0× | 0.00% |
| FY2016 | 0.0× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.3× | 4.57% |
| Mar 2026 | 0.2× | 560.33% |
| Dec 2025 | 0.0× | (30.43%) |
| Sep 2025 | 0.1× | (19.97%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IDXG Interpace Biosciences, Inc. | 0.9× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)